opioid use disorder
Pain · 2019–2021
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| buprenorphine Treatment of opioid dependence (opioid use disorder) within a framework of medical, social, and psychological treatment. The weekly formulation can be… | Nov 2021 | Recommended with restriction | 1 individuals Better Access Australia |
| buprenorphine Treatment of opioid use disorder (opioid dependence), within a framework of medical, social and psychological treatment. | Mar 2019 | Deferred | none received |
| buprenorphine Treatment of opioid use disorder within a framework of medical, social and psychological treatment, for patients stabilised on sublingual buprenorphine or… | Nov 2019 | Recommended | no section in document |
Who spoke
Better Access Australia
What the PBS pays
$183M in government benefit over 2024–25, across 1,909,959 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| buprenorphine | $182.7M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.